Experimental breast cancer treatment allows Florida woman to return to normal life


A trial of more than 10,000 women - including 690 Irish women - with the most common form of early breast cancer found the treatment was unnecessary for many after surgery. "We are de-escalating toxic therapy", Dr. Kathy Albain, chair of oncology research at Loyola University School of Medicine and lead researcher of the study, said. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer [published online June 3, 2018]. In fact, about 70 percent of women with hormone-receptor-positive, HER2-negative, node-negative breast cancer wouldn't benefit from chemo-that's about 70,000 women annually in the United States.

Previously in clinical trials, checkpoint inhibitors have proved ineffective against most breast cancers.

Lead author Dr Joseph Sparano, of Montefiore Medical Centre in NY, said: "Any women with early stage breast cancer 75 or younger should have the test and discuss the results of TAILORx with her doctor".

A WOMAN has been completely cured of breast cancer after doctors tweaked her immune system, enabling it to destroy the tumours that had spread through her body.

Oncotype Dx is a test created to predict the risk of breast cancer coming back.

A high recurrence score, above 25, means chemo is advised to ward off a recurrence, while a low score, below 10, means it is not.

However, there is still uncertainty about the benefit of chemotherapy for most patients who have a midrange score, they specified.

But most women get an intermediate result meaning they are unclear as to what to do.

"... Because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is, in a sense, a blueprint we can use for the treatment of many types of cancer", said Dr. Steven Rosenberg, the chief of the surgery branch at the National Cancer Institute's Center for Cancer Research.

It's a word that strikes fear into most, but with one in two people are diagnosed with cancer in their lifetime.

It took about eight weeks to craft the therapy for the breast-cancer patient. The 67 percent of women who were at intermediate risk all had surgery and hormone therapy.

Dr. Otis Brawley, chief medical and scientific officer for the American Cancer Society said that he was "delighted" by the study and anxious about unnecessary cancer treatment and the side effects that come from chemotherapy. In particular, the treatment hasn't been hugely successful in treating common epithelial cancers.

"Side effects, such as hair loss, severe pain and infertility, can be utterly devastating and linger long after they walk out the hospital doors".

Researchers at the national cancer institute have put a patient with metastatic breast cancer patient into complete remission using a new approach to immunotherapy. That comprises about 85 percent of women with breast cancer in this age group, the researchers noted. They say the data "provide evidence that that adjuvant chemotherapy was not beneficial in these patients". They also have a score between 11 and 25 on the Oncotype DX Breast Recurrence Score test.

"This research is experimental right now", said Dr Rosenberg.

"With the recent consultation on tumour profiling tests having already closed, it is crucial that Nice has the opportunity to consider these results as soon as possible", Baroness Morgan said.

That's why it's great news to hear that doctors in the U.S. have just made an unbelievable scientific breakthrough through, curing a woman who was in the advanced stages of the disease. "These kinds of tools allow us to make tailored medicine a reality, allowing us to offer the right therapy for the right patient at the right time".

Latest News